局部晚期前列腺癌生化失败时间间隔作为替代终点:随机试验NRG/RTOG 9202分析
基于NRG/RTOG 9202随机试验(N=1520)比较短期AD(4个月)与长期AD(LTAD;28个月),评估无生化失败时间间隔(IBF)与前列腺癌特异性生存(PCSS)和总生存(OS)的关系。LTAD在生化失败和临床终点上均优于短期AD。IBF满足替代终点标准,可识别LTAD对疾病特异性生存和OS的获益。
要点
- LTAD在生化失败和临床终点上均优于短期AD。
- 无生化失败3年者OS相对风险降低39%,PCSS相对风险降低73%。
- IBF满足替代终点标准,可能作为临床试验有效终点并辅助风险监测。
核心结论
- IBF满足替代终点标准,可识别LTAD对疾病特异性生存和OS的获益。
- IBF可能作为临床试验的有效终点,也可能辅助初始治疗后的风险监测。
研究设计与样本
- NRG/RTOG 9202随机试验(N=1520),比较短期AD(4个月)与长期AD(LTAD;28个月)。
- 采用生存建模和landmark分析方法评估LTAD对IBF和临床终点的获益、IBF与临床终点的关联以及IBF对LTAD临床终点获益的中介效应。
主要发现
- LTAD在生化失败和临床终点上均优于短期AD。
- 无生化失败3年者OS相对风险降低39%,PCSS相对风险降低73%。
- 考虑3年IBF状态后,LTAD的OS获益从12%(HR 0.88;95%CI 0.79至0.98)降至6%(HR 0.94;95%CI 0.83至1.07)。
- 考虑3年IBF状态后,LTAD的PCSS获益从30%(HR 0.70;95%CI 0.52至0.82)降至6%(HR 0.94;95%CI 0.72至1.22)。
- 在生化失败男性中,3年内后续死亡50%归因于前列腺癌,而无生化失败3年男性中为19%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In prostate cancer, end points that reliably portend prognosis and treatment benefit (surrogate end points) can accelerate therapy development. Although surrogate end point candidates have been evaluated in the context of radiotherapy and short-term androgen deprivation (AD), potential surrogates under long-term (24 month) AD, a proven therapy in high-risk localized disease, have not been investigated. MATERIALS AND METHODS: In the NRG/RTOG 9202 randomized trial (N = 1,520) of short-term AD (4 months) versus long-term AD (LTAD; 28 months), the time interval free of biochemical failure (IBF) was evaluated in relation to clinical end points of prostate cancer-specific survival (PCSS) and overall survival (OS). Survival modeling and landmark analysis methods were applied to evaluate LTAD benefit on IBF and clinical end points, association between IBF and clinical end points, and the mediating effect of IBF on LTAD clinical end point benefits. RESULTS: LTAD was superior to short-term AD for both biochemical failure (BF) and the clinical end points. Men remaining free of BF for 3 years had relative risk reductions of 39% for OS and 73% for PCSS. Accounting for 3-year IBF status reduced the LTAD OS benefit from 12% (hazard ratio [HR], 0.88; 95% CI, 0.79 to 0.98) to 6% (HR, 0.94; 95% CI, 0.83 to 1.07). For PCSS, the LTAD benefit was reduced from 30% (HR, 0.70; 95% CI, 0.52 to 0.82) to 6% (HR, 0.94; 95% CI, 0.72 to 1.22). Among men with BF, by 3 years, 50% of subsequent deaths were attributed to prostate cancer, compared with 19% among men free of BF through 3 years. CONCLUSION: The IBF satisfied surrogacy criteria and identified the benefit of LTAD on disease-specific survival and OS. The IBF may serve as a valid end point in clinical trials and may also aid in risk monitoring after initial treatment.
引用
- Dignam JJ, Hamstra DA, Lepor H, et al. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2018. PMID: 30526194. doi:10.1200/JCO.18.00154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。